Alector Inc.

Pipeline (1)

• LatozinemabBiologicSortilin Antagonist
  • Frontotemporal dementiaDiscontinuedDiscontinued
  • Amyotrophic lateral sclerosisDiscontinuedDiscontinued

Deals & partnerships

• Jul 2021Licensing dealGSK partners with Alector on latozinemab and AL101 ($700M upfront)GlaxoSmithKline and Alector announced a global collaboration in July 2021 to co-develop and co-commercialize Alector's two progranulin-elevating antibodies, latozinemab (AL001) and AL101 (GSK4527226), for frontotemporal dementia, ALS and other neurodegenerative diseases. Alector received $700 million upfront with up to $1.5 billion in potential milestones. GSK appears as collaborator on the INFRONT-2 and INFRONT-3 registry records, and latozinemab carried the GSK code GSK4527223. Recorded compound-wide (the deal spans both antibodies and multiple indications).Latozinemabsource ↗

Catalysts · 0 upcoming · 1 reported

Recently reported

• 2025-10-21missed

  LatozinemabforFrontotemporal dementiaTopline data

  Phase 3 INFRONT-3 failed: latozinemab significantly raised plasma progranulin (biomarker co-primary met) but did not slow FTD-GRN clinical progression on CDR plus NACC FTLD-SB (clinical co-primary missed); open-label extension and continuation study discontinued.

  source ↗

Recent activity

• Oct 21, 2025ReadoutLatozinemab·Frontotemporal dementiamissedPhase 3 INFRONT-3 failed: latozinemab significantly raised plasma progranulin (biomarker co-primary met) but did not slow FTD-GRN clinical progression on CDR plus NACC FTLD-SB (clinical co-primary missed); open-label extension and continuation study discontinued.source ↗
• Oct 28, 2022Phase changeLatozinemab·Amyotrophic lateral sclerosisDiscontinuedThe Phase 2 ALS study was terminated after enrolling 5 participants. Registry whyStopped: 'The Sponsor is considering a subsequent study in ALS, potentially with different inclusion/exclusion criteria.' No subsequent ALS study was ever registered, and all latozinemab development ended 2025-10-21 after the FTD Phase 3 failure — so this termination date stands as the program's end.source ↗
• Sep 2, 2021Phase changeLatozinemab·Amyotrophic lateral sclerosisPhase 2Phase 2 study of latozinemab in C9orf72-associated ALS (AL001-ALS-201, NCT05053035) started, targeting 45 participants — the first expansion of the progranulin-elevation hypothesis beyond FTD, two months after the GSK collaboration was announced.source ↗
• Jul 23, 2020Phase changeLatozinemab·Frontotemporal dementiaPhase 3INFRONT-3 (NCT04374136) pivotal Phase 3 started: randomized, double-blind, placebo-controlled, 96-week study of latozinemab 60 mg/kg IV every 4 weeks in FTD-GRN; 119 enrolled (101 symptomatic patients in the primary analysis population). Co-primary endpoints: plasma progranulin concentration and CDR plus NACC FTLD-SB.source ↗
• Sep 27, 2019Phase changeLatozinemab·Frontotemporal dementiaPhase 2INFRONT-2 (NCT03987295) open-label Phase 2 started: 33 participants with GRN or C9orf72 mutations, latozinemab 60 mg/kg IV every 4 weeks. Twelve-month data (July 2021) showed maintained normal progranulin levels, normalization of disease-associated fluid biomarkers, and stabilized neurofilament light chain with potential clinical benefit — the basis for the 2024 Breakthrough Therapy designation.source ↗
• Sep 14, 2018Phase changeLatozinemab·Frontotemporal dementiaPhase 1INFRONT-1 (NCT03636204) first-in-human study started: single and multiple ascending IV doses in 64 healthy volunteers and asymptomatic/symptomatic GRN mutation carriers. July 2019 results: generally safe and well tolerated, dose-dependent progranulin increases in plasma and CSF including a doubling of CSF progranulin concentration.source ↗

Competitive landscape

Other companies developing against Alector Inc.'s targets or indications.

• AB Science1 compoundAmyotrophic lateral sclerosis
• Ionis Pharmaceuticals, Inc.1 compoundAmyotrophic lateral sclerosis